« Back
Home /
Pioglitazone

Pioglitazone

Item no.	HY-13956-50mg
Manufacturer	MedChem Express
CASRN	111025-46-8
Amount	50 mg
Quantity options	10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Diabetes Cholesterol & Lipid Metabolism Regulation of Appetite Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Colorectal Cancer Testicular & Prostate Cancer Neurodegeneration Markers
Type	Inhibitors
Specific against	other
Purity	99.89
Citations	[1]Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve\|[2]Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84.\|[3]Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55.\|[4]Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. Acta Pharmacol Sin. 2021 Jan;42(1):160-170.\|Adv Sci (Weinh). 2024 Dec 25:e2407134.\|Adv Sci (Weinh). 2024 Oct 7:e2401931.\|Am J Physiol Heart Circ Physiol. 2021 Apr 9.\|Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F137-F151.\|Biochem Eng J. 2021, 108104.\|BMC Complement Med Ther. 2022 Jul 1;22(1):176.\|Br J Pharmacol. 2021 Jun;178(11):2305-2323.\|Cancer Res. 2022 Apr 15;82(8):1503-1517.\|Cell Metab. 2021 Mar 2;33(3):581-597.e9.\|Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.\|Food Chem Toxicol. 2021 Apr 6;112183.\|Gut Microbes. 2022, 14(1): 2139978.\|Heliyon. 2023 Apr 1.\|Immunology. 2023 Jan 28.\|Immunopharmacol Immunotoxicol. 2021 Aug 27;1-9.\|J Adv Res. 2024 Sep 29:S2090-1232(24)00427-2.\|J Ethnopharmacol. 2024 Nov 29:340:119128.\|J Steroid Biochem Mol Biol. 2023 Feb 1;229:106265.\|Med Sci Monit. 2019 Nov 13;25:8544-8553.\|Nutr Metab (Lond). 2019 Mar 5;16:17. \|Oxid Med Cell Longev. 2022.\|Res Sq. 2024 Jul 12.\|Research Square Preprint. 2021 Mar.\|SSRN. 2023 May 30.\|Tunku Abdul Rahman University. 2024 Mar 11.\|Inflammation. 2020 Apr;43(2):568-578.\|Int J Oncol. 2018 Aug;53(2):551-566.\|J Diabetes Res. 2019 Feb 3;2019:5245063.\|Mol Med Rep. 2024 Nov;30(5):209.\|Mol Med Rep. 2019 Jan;19(1):400-406.
Smiles	O=C(N1)SC(CC2=CC=C(OCCC3=NC=C(CC)C=C3)C=C2)C1=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	U 72107
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Ferroptosis; PPAR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	356.44
Product Description	Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research[2][3][4].
Manufacturer - Research Area	Metabolic Disease; Cancer
Solubility	DMSO: 25 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Isoform	PPARα; PPARβ/δ; PPARγ
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13956-50mg-safety-datasheet.pdf